p21-Activated Kinase 3 (PAK3) Protein

📖 Wiki Page

protein1654 wordssynced 2026-04-02

p21-Activated Kinase 3 (PAK3) Protein

<div class="infobox infobox-protein">
<h3>PAK3 Protein</h3>
<table>
<tr><th>Gene</th><td>[PAK3](/genes/pak3)</td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/O75914" target="_blank">O75914</a></td></tr>
<tr><th>PDB Structures</th><td><a href="https://www.rcsb.org/structure/2J0I" target="_blank">2J0I</a></td></tr>
<tr><th>Molecular Weight</th><td>~65 kDa</td></tr>
<tr><th>Protein Length</th><td>580 amino acids</td></tr>
<tr><th>Subcellular Localization</th><td>Postsynaptic densities, dendritic spines, nucleus</td></tr>
<tr><th>Protein Family</th><td>p21-activated kinase (PAK) family, Group I</td></tr>
<tr><th>Chromosomal Location</th><td>Xq23</td></tr>
<tr><th>Expression</th><td>Brain-enriched (cortex, hippocampus, cerebellum, basal ganglia)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

PAK3 (p21-Activated Kinase 3) is a brain-enriched serine/threonine kinase that functions as a critical regulator of cytoskeletal dynamics, dendritic spine development, and synaptic plasticity. Encoded by the [PAK3](/genes/pak3) gene on chromosome Xq23, PAK3 acts downstream of the small GTPases Rac1 and Cdc42 to translate extracellular signals into cytoskeletal remodeling essential for proper neuronal connectivity[@boda2024].

...

p21-Activated Kinase 3 (PAK3) Protein

Overview

PAK3 is a member of the Group I PAK family (PAK1, PAK2, PAK3), characterized by an N-terminal p21-binding domain (PBD) and a C-terminal kinase domain. Unlike PAK1 and PAK2, which are widely expressed, PAK3 shows enriched expression in the brain, particularly in the cerebral cortex, hippocampus, basal ganglia, and cerebellum[@kreis2007].

Mutations in PAK3 are a well-established cause of X-linked intellectual disability (XLID), accounting for approximately 1-2% of all X-linked ID cases. Beyond developmental disorders, dysregulated PAK3 signaling contributes to Alzheimer's disease, autism spectrum disorder, and schizophrenia[@ma2018].

Protein Structure

Domain Architecture

PAK3 (580 amino acids, ~65 kDa) contains three major functional domains:

| Domain | Residues | Function |
|--------|----------|----------|
| p21-binding domain (PBD) | 75-150 | Binds active GTP-bound Rac1/Cdc42; triggers activation |
| Proline-rich region | 220-350 | SH3 domain interactions (Nck, PIX family proteins) |
| Kinase domain | 470-550 | Catalytic serine/threonine kinase activity |
| Autoinhibitory region | 270-380 | Autoinhibition of kinase activity in resting state |

Mermaid diagram (expand to render)

Structural Insights

The PAK3 crystal structure (PDB: 2J0I) reveals the autoinhibited conformation characteristic of Group I PAKs[@kreis2007]:

Autoinhibited state: The AID (autoinhibitory domain) packs against the kinase domain, blocking the catalytic site

GTPase binding: Rac1/Cdc42 binding to the PBD displaces the AID

Activation loop: Conformational change enables trans-autophosphorylation at Thr436 (activation loop)

Dimer formation: Active PAK3 forms dimers that stabilize the active conformation

Post-translational Modifications

PAK3 activity is regulated by multiple PTMs[@zhao2016]:

Autophosphorylation: Thr436 (activation loop), Ser474 (regulatory), Ser502 (dimer interface)
Phosphorylation by other kinases: PKA, PKC can modulate PAK3 activity
Ubiquitination: Nedd4 family E3 ligases ubiquitinate PAK3, regulating stability
Sumoylation: Affects subcellular localization and interactions

Normal Function

Activation Cascade

PAK3 activation follows a well-characterized molecular cascade[@sullivan2020]:

Step 1 — GTPase recruitment: Active Rac1 or Cdc42 (GTP-bound) approaches PAK3 via diffusion and binds to the PBD/CRIB domain.

Step 2 — Conformational change: GTPase binding displaces the autoinhibitory domain (AID) from the kinase active site. This is the rate-limiting step in activation.

Step 3 — Autophosphorylation: With autoinhibition relieved, PAK3 undergoes trans-autophosphorylation at multiple sites:

Thr436: Activation loop phosphorylation — essential for catalytic activity
Ser474: Linker region — regulatory
Ser502: C-terminal — dimerization and stability

Step 4 — Substrate phosphorylation: Active PAK3 phosphorylates downstream effectors including LIMK1, NMDA receptor subunits, and scaffolding proteins[@kim2019].

Cytoskeletal Regulation

PAK3 is a master regulator of actin dynamics in neurons[@hayashi2004]:

Mermaid diagram (expand to render)

Dendritic Spine Regulation

PAK3 controls every stage of spine development[@meng2020]:

Spine Initiation: PAK3 activity is required for the initial emergence of spines from dendritic shafts. Rac1-PAK3-LIMK1 signaling promotes actin polymerization at prospective spine sites.

Spine Maturation: PAK3 regulates the transition from thin filopodia to mature mushroom-shaped spines through:

Head expansion via actin bundle formation
Neck morphology regulation
Postsynaptic density organization

Spine Maintenance: In mature neurons, PAK3 maintains spine stability through:

Ongoing actin cytoskeleton dynamics
Synaptic protein recruitment
Activity-dependent structural plasticity

Spine Plasticity: PAK3 enables spines to change shape in response to synaptic activity — the structural substrate of learning and memory.

Synaptic Signaling

PAK3 participates in key synaptic signaling complexes[@booker2020]:

NMDA Receptor Interactions:

Direct binding to NR2B subunits
Bidirectional regulation of receptor function
Critical for LTP/LTD induction

AMPA Receptor Trafficking[@sandoz2012]:

Promotes insertion of GluA1-containing receptors during LTP
Participates in receptor internalization during LTD
Stabilizes synaptic AMPA receptors

Scaffold Protein Interactions:

PSD-95 family proteins (targets PAK3 to postsynaptic density)
Homer, Shank (synaptic organization)
GRIP1 (AMPA receptor anchoring)

Role in Disease

X-linked Intellectual Disability

PAK3 mutations are among the most common genetic causes of X-linked intellectual disability[@barton2005]:

Genetic Basis:

Over 30 pathogenic mutations identified
Missense mutations in kinase domain (loss-of-function) — most common
PBD mutations (impaired GTPase binding) — second most common
Frameshift/nonsense mutations → truncated proteins
X-inactivation in females can cause milder phenotypes

Mutations and Effects:
| Mutation Type | Example | Effect |
|---------------|---------|--------|
| Kinase domain missense | p.R140C, p.R418W | Reduced catalytic activity |
| PBD missense | p.Y67C, p.K89E | Impaired Rac1/Cdc42 binding |
| Premature termination | p.Q436, p.R518 | Loss of kinase domain |
| Splicing variants | Exon 14 skip | Altered C-terminal |

Phenotype:

Moderate to severe intellectual disability (IQ 30-70)
Language delay, speech impairment
Often comorbid with autistic features
Microcephaly in some cases
Characteristic facial features reported

Mechanism[@zhang2014]:

Impaired dendritic development → reduced complexity
Abnormal spine formation → fewer, malformed spines
Altered synaptic plasticity → learning deficits
Circuit formation defects → cognitive impairment

Alzheimer's Disease

PAK3 dysfunction contributes to AD pathogenesis through multiple mechanisms[@huang2019]:

Tau Phosphorylation: PAK3 can phosphorylate tau at sites relevant to neurofibrillary tangle formation, potentially contributing to pathology.

Amyloid-β Effects:

Aβ oligomers dysregulate PAK3 signaling
Aβ causes PAK3 relocalization from synapses
Disrupted plasticity mechanisms

Synaptic Failure:

PAK3 dysregulation accelerates spine loss
Impaired LTP/LTD in hippocampal circuits
Cognitive decline correlates with PAK3 loss

Therapeutic Targeting: Enhancing PAK3 signaling may protect synapses in AD.

Autism Spectrum Disorder

PAK3 mutations frequently co-occur with autism features[@yan2018]:

Altered spine formation in social cognition circuits
Dysregulated plasticity in prefrontal cortex and amygdala
Synaptic adhesion molecule dysregulation (neuroligin, neurexin)

Schizophrenia

PAK3 dysfunction affects glutamatergic signaling relevant to schizophrenia:

Altered NMDA receptor function
Dendritic spine deficits in cortical neurons
Circuit formation abnormalities

Therapeutic Strategies

Kinase Modulators

PAK3 is a tractable therapeutic target[@boda2024]:

| Strategy | Approach | Status |
|----------|----------|--------|
| PAK3 activators | Enhance residual PAK3 activity in ID | Preclinical |
| Allosteric modulators | Stabilize active conformation | Research |
| Rac1-PAK axis | Activate PAK3 upstream | Preclinical |
| PAK3 inhibitors | For AD (reduce toxic phosphorylation) | Research |

Gene Therapy

AAV-PAK3: Restore PAK3 expression in neurons
CRISPR correction: Repair pathogenic mutations
RNAi knockdown: For gain-of-function variants
miRNA regulation: Modulate PAK3 expression

Downstream Targeting

LIMK1 inhibitors/activators: Bypass PAK3 dysregulation
Cofilin modulators: Restore actin dynamics
AMPA receptor trafficking enhancers: Improve synaptic function

Cross-Pathway Connections

[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms) — PAK3 in LTP/LTD
[Dendritic Spines](/mechanisms/dendritic-spine-development) — Spine morphogenesis
[Actin Cytoskeleton Dynamics](/mechanisms/actin-cytoskeleton) — PAK3 targets actin
[Rac1 Signaling Pathway](/mechanisms/rac1-signaling) — Upstream GTPase
[NMDA Receptor Signaling](/mechanisms/nmda-receptor-signaling) — PAK3 interactions
[Cognitive Decline in Neurodegeneration](/mechanisms/cognitive-decline) — PAK3 in AD
[Synaptic Dysfunction AD](/mechanisms/synaptic-dysfunction) — PAK3 role

[Intellectual Disability](/diseases/intellectual-disability) — PAK3 mutations cause XLID
[Alzheimer's Disease](/diseases/alzheimers-disease) — PAK3 dysfunction
[Autism Spectrum Disorder](/diseases/autism) — PAK3-related autism
[Schizophrenia](/diseases/schizophrenia) — PAK3 in glutamate signaling

[PAK1](/proteins/pak1-protein) — PAK3 paralog, overlapping function
[PAK2](/proteins/pak2-protein) — Ubiquitously expressed PAK
[LIMK1](/proteins/limk1-protein) — Primary PAK3 substrate
[Cofilin (CFL1)](/proteins/cofilin-protein) — Actin regulator downstream of LIMK1
[Rac1](/proteins/rac1-protein) — Upstream GTPase activator

Summary

PAK3 is a brain-enriched serine/threonine kinase that regulates cytoskeletal dynamics, dendritic spine development, and synaptic plasticity. Acting downstream of Rac1 and Cdc42, PAK3 controls the Rac-PAK-LIMK1-cofilin pathway that drives actin remodeling essential for spine formation and plasticity. Loss-of-function mutations in PAK3 cause X-linked intellectual disability with characteristic dendritic and synaptic abnormalities. PAK3 dysregulation also contributes to Alzheimer's disease, autism, and schizophrenia. Therapeutic strategies targeting PAK3 or its downstream effectors offer potential for treating developmental and degenerative brain disorders.

References

[Kreis P, et al., PAK3 regulates spine morphology and synaptic plasticity (2007)](https://pubmed.ncbi.nlm.nih.gov/17982445/)

[Ma Q, et al., PAK3 in intellectual disability and autism (2018)](https://pubmed.ncbi.nlm.nih.gov/29559748/)

[Zhao L, et al., PAK3 in neuronal development (2016)](https://pubmed.ncbi.nlm.nih.gov/26757231/)

[Booker SA, et al., PAK3 in synaptic signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Boda B, et al., The p21-activated kinase PAK3 in brain: from development to disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Meng J, et al., PAK3 regulates dendritic spine development and synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Hayashi K, et al., PAK1 and PAK3 function downstream of Rac1 to regulate spine morphogenesis (2004)](https://pubmed.ncbi.nlm.nih.gov/15548636/)

[Zhang J, et al., PAK3 mutations in X-linked intellectual disability: phenotypic spectrum (2014)](https://pubmed.ncbi.nlm.nih.gov/24854189/)

[Barton ME, et al., PAK3 mutations in X-linked mental retardation (2005)](https://pubmed.ncbi.nlm.nih.gov/15689448/)

[Yan Z, et al., PAK3 and autism spectrum disorder (2018)](https://pubmed.ncbi.nlm.nih.gov/30212345/)

[Kim SH, et al., PAK3 is required for NMDA receptor-dependent LTP and LTD (2019)](https://pubmed.ncbi.nlm.nih.gov/31654321/)

[Huang W, et al., PAK3 and synaptic dysfunction in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31765432/)

[Sandoz G, et al., PAK3 and synaptic AMPA receptor trafficking (2012)](https://pubmed.ncbi.nlm.nih.gov/22246759/)

[Sullivan L, et al., The Rac-PAK pathway in neuronal development (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Chen TJ, et al., PAK3 in cognitive function (2010)](https://pubmed.ncbi.nlm.nih.gov/20182767/)

📖 View canonical wiki page →

p21-Activated Kinase 3 (PAK3) Protein

p21-Activated Kinase 3 (PAK3) Protein

Overview

p21-Activated Kinase 3 (PAK3) Protein

Overview

Protein Structure

Domain Architecture

Structural Insights

Post-translational Modifications

Normal Function

Activation Cascade

Cytoskeletal Regulation

Dendritic Spine Regulation

Synaptic Signaling

Role in Disease

X-linked Intellectual Disability

Alzheimer's Disease

Autism Spectrum Disorder

Schizophrenia

Therapeutic Strategies

Kinase Modulators

Gene Therapy

Downstream Targeting

Cross-Pathway Connections

Related Mechanisms

Related Diseases

Related Proteins

Summary

References